|
|
Post by ktim on Dec 9, 2023 15:58:10 GMT -5
If prescribers get persuaded to prescribe Afrezza, school nurses will see it in the DMMP. The IHP and the Section 504 plan is influenced by school nurses. There are opportunities to influence what is in these. If we think updating the Standard of Care is possible and important, then influencing DMMPs, IHPs and 504s is possible and important too. The doctor prescribes. That's a given regardless of whether they prescribe Afrezza or Humalog. Schools can say, " we prefer the doctor prescribe Afrezza because of the SAFETY and reduced likelihood of hypoglycemia". I'm not sure it needs to get more complicated than that. If I was a MannKind rep, and the results of the Pediatric study say Afrezza is safer and superior, than I'm going to tell it to whoever will listen and can influence prescribers and I would target getting in front of my state's school nurse association to let them know safer, superior, convenient. Presently the doctor would then likely say that there is no clinical trails showing superior outcomes and that the kids insurance doesn't cover Afrezza. Of course that part you've stated about meaningfully superior results on peds trial being a game changer is probably the key. That would change physicians views and insurance coverage. |
|
|
|
Post by sayhey24 on Dec 9, 2023 17:42:53 GMT -5
I am thinking the dinner is more of an educational session on diabetes and blood glucose and the basics of the issues these kids are facing with taking insulin and the benefits of afrezza. If the rep could bring two live adults diabetics and did the coke challenge live with live CGM of one taking afrezza and one taking an injection.
Of course step 1 is getting afrezza approved for the kids.
|
|
|
|
Post by agedhippie on Dec 10, 2023 3:10:54 GMT -5
... The doctor prescribes. That's a given regardless of whether they prescribe Afrezza or Humalog. Schools can say, " we prefer the doctor prescribe Afrezza because of the SAFETY and reduced likelihood of hypoglycemia". ... Presently the doctor would then likely say that there is no clinical trails showing superior outcomes and that the kids insurance doesn't cover Afrezza. Of course that part you've stated about meaningfully superior results on peds trial being a game changer is probably the key. That would change physicians views and insurance coverage. TBH none of that matters because there is absolutely no way the school would ever express an opinion on a drug because of the liability risk. If they were insane enough to actually do it and you went back to the endo and asked them to change the treatment they prescribed based on the advice of a school nurse it would not end well. |
|
|
|
Post by agedhippie on Dec 10, 2023 3:17:20 GMT -5
The school nurses and Trained Diabetes Personnel (TDP) could also benefit from a demonstration (using BlueHale??) and some information about dosing and administration. I wonder if there are placebo cartridges for demonstrations? A demo would be good and could be justified as ensuring that the doctor's orders are correctly followed. I would frame it as being the same as teaching correct injecting technique. Dosing and administration would be off-limits though as that is prescribed in the plan by the doctor. The nurse is not allowed to stray off the plan since they are there to administer the it and not to modify it which would be the doctor's role. |
|
|
|
Post by prcgorman2 on Dec 10, 2023 9:34:45 GMT -5
The school nurses and Trained Diabetes Personnel (TDP) could also benefit from a demonstration (using BlueHale??) and some information about dosing and administration. I wonder if there are placebo cartridges for demonstrations? A demo would be good and could be justified as ensuring that the doctor's orders are correctly followed. I would frame it as being the same as teaching correct injecting technique. Dosing and administration would be off-limits though as that is prescribed in the plan by the doctor. The nurse is not allowed to stray off the plan since they are there to administer the it and not to modify it which would be the doctor's role. Agree about following doctor’s orders. Was thinking some education about the different colored cartridges, use and disposal (do people rinse the cartridges before disposal?), care and cleaning (if appropriate) of the inhaler, and then some education about what the school nurse and/or TDP should expect with regard to dosing. e.g., possible follow-up dose after lunch if needed. Answer any questions like affects on lung function, et cetera. Educating the educators. |
|
|
|
Post by akemp3000 on Dec 10, 2023 11:18:00 GMT -5
Yes. A family member has been on the speaker circuit for several of the best known global BPs. When a new drug is to be introduced, the drug company summons them to Chicago, LA or wherever for two or three days to be trained on the presentation and precisely what they legally can and can't say. They return to their region to train doctors and nurses how and when to prescribe and use the new drug. Off-label is not discussed. This is hugely beneficial in gaining acceptance.
|
|
|
|
Post by cretin11 on Dec 10, 2023 13:11:20 GMT -5
… for several of the best known global BPs. Yes, one of those is what we need if we are to justify expending resources on this type of idea. |
|
|
|
Post by prcgorman2 on Dec 11, 2023 8:17:47 GMT -5
Sez you.. MannKind does sales training events too, and some of the VDEX folks would make good guests.
|
|
|
|
Post by cretin11 on Dec 11, 2023 8:35:16 GMT -5
Sez you.. MannKind does sales training events too I’m sure they do, but my preference is to get more traction than 900 TRx in seven years. Some companies have proven their ability to deliver sales results with groundbreaking drugs, I would love it if such a company were selling Afrezza. This would be great for MNKD shareholders and PWDs. |
|
|
|
Post by ryster505 on Dec 11, 2023 10:51:05 GMT -5
Sez you.. MannKind does sales training events too I’m sure they do, but my preference is to get more traction than 900 TRx in seven years. Some companies have proven their ability to deliver sales results with groundbreaking drugs, I would love it if such a company were selling Afrezza. This would be great for MNKD shareholders and PWDs. Insurance, Insurance, Insurance, Insurance, Insurance, Insurance. People are acting like this is solely a Mannkind sales force problem. It’s not. We know this. |
|
|
|
Post by prcgorman2 on Dec 11, 2023 10:52:36 GMT -5
Sez you.. MannKind does sales training events too I’m sure they do, but my preference is to get more traction than 900 TRx in seven years. Some companies have proven their ability to deliver sales results with groundbreaking drugs, I would love it if such a company were selling Afrezza. This would be great for MNKD shareholders and PWDs. The way you sweep facts (and commentary from folks like agedhippie, stevil, and others) aside in your efforts to paint MannKind management as incompetent is breath-taking. I'm not against BP partners (unless they act like Sanofi) but your claim improved sales of Afrezza is only possible if somebody other than MannKind markets it is hackneyed and tiresome. |
|
|
|
Post by cretin11 on Dec 11, 2023 11:22:29 GMT -5
I’m sure they do, but my preference is to get more traction than 900 TRx in seven years. Some companies have proven their ability to deliver sales results with groundbreaking drugs, I would love it if such a company were selling Afrezza. This would be great for MNKD shareholders and PWDs. The way you sweep facts (and commentary from folks like agedhippie, stevil, and others) aside in your efforts to paint MannKind management as incompetent is breath-taking. I'm not against BP partners (unless they act like Sanofi) but your claim improved sales of Afrezza is only possible if somebody other than MannKind markets it is hackneyed and tiresome. "breath-taking"? So dramatic. I suggest slow down, focus and yes: take a breath. Then if you read my post again, more carefully and without jumping to assumptions, you'll see there are three sentences, none of which are inaccurate. My post is a perfectly reasonable take. That is, if you're a MNKD long. I could've ridiculed your notion that having show-and-tells with school nurses would move the needle, but I was polite and even complimented your "outside the box" thinking. It's the holiday season, time to be of good cheer. On the other hand, you stand ready to negatively pounce on any post I make that isn't full of your desired quotient of hopium. And that's your prerogative. But you choose to insult me without countering the substance of my post, which is telling. |
|
|
|
Post by BD on Dec 11, 2023 11:43:24 GMT -5
I’m sure they do, but my preference is to get more traction than 900 TRx in seven years. Some companies have proven their ability to deliver sales results with groundbreaking drugs, I would love it if such a company were selling Afrezza. This would be great for MNKD shareholders and PWDs. The way you sweep facts (and commentary from folks like agedhippie, stevil, and others) aside in your efforts to paint MannKind management as incompetent is breath-taking. I'm not against BP partners (unless they act like Sanofi) but your claim improved sales of Afrezza is only possible if somebody other than MannKind markets it is hackneyed and tiresome. This doesn't quite rise to the level of my taking any moderation action, but to me it seems the level of vitriol here against cretin is most certainly out of proportion to the post you're replying to and maybe a wee bit too personal. There are members here with considerable MNKD burnout (I know of at least one for sure lol) and I suspect it's more than just me who can say we feel at least the same way cretin does, or maybe even more harshly toward the company. It's OK to feel that way, and to express it. Really. |
|
|
|
Post by celo on Feb 25, 2024 11:56:04 GMT -5
The first 17 weeks of the trial with the primary outcome will occur March 5th. I am assuming, there will be a bit of time to do dissemination of the results before the release of data. There is also a 13 week extension, ends June 4th, which is for all patients to use inhaled insulin, even the ones in the control group.
Will there be any results of the study released before June 4th or do we have to wait until October when the study is said to be completed?
Could be the year for Afrezza to really build momentum or not.
|
|
|
|
Post by celo on Feb 27, 2024 20:39:54 GMT -5
The first 17 weeks of the trial with the primary outcome will occur March 5th. I am assuming, there will be a bit of time to do dissemination of the results before the release of data. There is also a 13 week extension, ends June 4th, which is for all patients to use inhaled insulin, even the ones in the control group. Will there be any results of the study released before June 4th or do we have to wait until October when the study is said to be completed? Could be the year for Afrezza to really build momentum or not. Thanks Mike for answering my question. Sounds like the first 17 week results will be discussed at the ATTD Diabetes congress March 6-9th, next week. Can't wait for the results! |
|
